AKT1 and depressive disorder: However, in another dexamethasone-induced depression model, rosiglitazone exerts antidepressant effects via NGF activation and decreases the levels of phosphorylated AKT and mechanistic target of rapamycin kinase (mTOR), which conflicts with the conclusions above (Alhaddad et al. 2023).